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Psychological impact of human papillomavirus testing in women
with borderline or mildly dyskaryotic cervical smear test results:
cross sectional questionnaire study
Esther Maissi, Theresa M Marteau, Matthew Hankins, Sue Moss, Rosa Legood, Alastair Gray
Abstract
Objective To describe the psychological impact on women of
being tested for human papillomavirus (HPV) when smear test
results are borderline or mildly dyskaryotic.
Design Cross sectional questionnaire study.
Setting Two centres participating in an English pilot study of
HPV testing in women with borderline or mildly dyskaryotic
smear test results.
Participants Women receiving borderline or mildly dyskaryotic
smear test results tested for HPV and found to be HPV positive
(n = 536) or HPV negative (n = 331); and women not tested for
HPV with borderline or mildly dyskaryotic smear results
(n = 143) or normal smear results (n = 366).
Main outcome measures State anxiety, distress, and concern
about test result, assessed within four weeks of receipt of results.
Results Women with borderline or mildly dyskaryotic smear
results who were HPV positive were more anxious, distressed,
and concerned than the other three groups. Three variables
independently predicted anxiety in HPV positive women:
younger age (= − 0.11, P = 0.03), higher perceived risk of
cervical cancer (= 0.17, P < 0.001), and reporting that they did
not understand the meaning of test results (= 0.17, P = 0.001).
Testing HPV negative was not reassuring: among women with
abnormal smear test results, those who were HPV negative were
no less anxious than those who were not tested for HPV.
Conclusions Informing women more effectively about the
meaning of borderline or mildly dyskaryotic smear test results
and HPV status, in particular about the absolute risks of cervical
cancer and the prevalence of HPV infection, may avoid some
anxiety for those who are HPV positive while achieving some
reassurance for those who test HPV negative.
Introduction
Human papillomavirus (HPV) is present in almost 100% of cer-
vical cancers1 and HPV positivity is associated with high grade
pre-invasive lesions in women with borderline nuclear change or
mild dyskaryosis. Given the relatively high rates of borderline or
mildly dyskaryotic cervical smear test results, HPV testing could
be used to stratify women for higher or lower risks of developing
cervical cancer, and to manage them accordingly. A pilot study
was mounted in England to evaluate the clinical, economic, and
psychological consequences of this strategy; this paper assesses
the psychological consequences.
Testing for human papillomavirus is expected to provide
clearer and more effective management strategies, but there are
concerns about its potential to raise anxiety beyond the levels
reported after women receive a borderline or mildly dyskaryotic
smear test result.2 Receiving abnormal smear test results and
being referred for colposcopic examination of the cervix are
associated with high anxiety levels,3–5 some of which can be
avoided by providing clear, salient information.6 7 No data are yet
available on the psychological impact of HPV testing in conjunc-
tion with cytological screening. Surveys of highly selected groups
of women who have undergone HPV testing for a variety of rea-
sons have had equivocal findings, with some showing raised lev-
els of distress8–11 and others not.12 13
Although HPV testing may raise anxiety in women who test
positive, it has the potential to reassure those who test negative
that their risks of developing cervical cancer, given a borderline
or mildly dyskaryotic smear test result, are lower than women
who with HPV infection.1 This study aimed to describe the psy-
chological impact of HPV testing in women with borderline or
mildly dyskaryotic cervical smear test results and to examine the
predictors of this impact.
Methods
Participants
All women who had a routine cervical smear test at two of the
three centres taking part in the English pilot study of liquid
based cytology and HPV testing, and who received either a nor-
mal or a borderline or mildly dyskaryotic test result, were eligible
for this study. They were informed about the possibility of being
invited into this questionnaire based study by the letter inviting
them to attend for screening. All borderline or mildly dyskaryo-
tic smear samples were tested for human papillomavirus. After
HPV testing in the pilot study, we recruited an extra group of
women with borderline or mildly dyskaryotic smear test results,
but no HPV testing, to assess the possible reassuring effects of
receiving an HPV negative test result.
All women with borderline or mildly dyskaryotic test results
over a five month period were invited to participate, as were the
first 13 women each week who received a normal test result (we
estimated this number was needed to achieve similar numbers in
each group). When the pilot was completed, the first 42 women
each week over a five week period with borderline or mildly dys-
karyotic results but no HPV test results were also recruited, half
from each of the two centres. In total, 2183 women were sent
questionnaires within a week of the research team being
informed that their smear test results had been sent to them. Up
to two reminders were sent. The final sample of 1376 (63%)
women comprised 366 women who had received a normal result
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and 1010 who had received a borderline or mildly dyskaryotic
smear test result. In the latter group 331 were HPV negative, 536
were HPV positive, and 143 had not been tested.
Clinical management
The box shows the written information that accompanied the
test results. Clinical management varied according to test result
and sometimes across centres.
Borderline or mildly dyskaryotic test result, HPV positive—In cen-
tre 1 all HPV positive women were referred for colposcopy. In
centre 2, due to an increased workload in the colposcopy clinics,
only women over 35 were referred for colposcopy. Those below
35 were invited for a repeat smear and HPV test after six months.
If dyskaryosis or HPV infection persisted, these women were
referred for colposcopy.
Borderline or mildly dyskaryotic test result,HPV negative—In both
centres women were asked to attend for a repeat smear and HPV
test six months later. If dyskaryosis, HPV infection, or both, was
found, women were referred for colposcopy.
Borderline or mildly dyskaryotic test result, HPV not tested—In
both centres, women with this result were asked to attend for a
repeat smear test after six months. If the repeat smear showed
borderline changes, mild dyskaryosis, or worse, women were
referred for colposcopy.
Normal smear test result—Women receiving a normal result
with no previous abnormal smear test results were returned to
routine recall.
Study hypotheses
Women with normal results were predicted to have anxiety
scores in the normal range (mean score = 35.0), while those with
borderline or mildly dyskaryotic results who were HPV negative
or not tested were predicted to have raised anxiety (mean
score = 38.0), with the highest levels of anxiety to be found in
HPV positive women (mean score = 40.0). The formal hypoth-
eses tested were that women with normal results would have
anxiety scores significantly lower than all other groups; that
women with borderline or mildly dyskaryotic smear test results
who were HPV positive would have significantly higher scores
than the other three groups; and that women with borderline or
mildly dyskaryotic smear test results who were HPV negative
would have lower anxiety scores than those who had abnormal
smear test results but had not been tested for HPV.
Given a population standard deviation of 12.0, a minimum of
115 women was required in each of the four groups to detect the
predicted small to medium effects (F= 0.16),14 with 80% power at
the 5% level of significance. This sample size was also sufficient
for pairwise comparisons to detect a mean difference of 0.37 of a
standard deviation between groups, with 80% power.
Outcome measures
State anxiety was assessed using the short form of the state scale
of the Spielberger state-trait anxiety inventory (S-STAI-6),15 pro-
rated to give a scale range from 20 to 80. The population norm
for women is 35; scores above 49 are found in patients with a
diagnosis of anxiety disorder. The internal reliability of the scale
in this study sample (n = 1288) was 0.84 (Cronbach’s ).
General distress was assessed using the 12 item general health
questionnaire (range 1-12) with a clinical cutoff score of 4
(= 0.89, n = 1343).16
Concern about the smear result was assessed using two seven
point rating scales (range 2-14) asking women how concerned,
and how reassured, they felt about the result. Higher scores indi-
cated more concern (= 0.66, n = 1352).
Perceived risk of developing cervical cancer was assessed using a
seven point scale assessing women’s perceptions of their
likelihood of developing cervical cancer in the next 10 years.
Written information provided to women with results of
smear test
Borderline or mildly dyskaryotic test result, HPV positive
These [minor abnormalities] are not cancer. A minor
abnormality means that there are small changes to the cells of
your cervix. This is not unusual. Because your result showed
these changes your sample was tested for the Human Papilloma
Virus (HPV). HPV is a very common infection of the cervix. Most
women get the virus at some point in their life. In most cases it
does not need treatment and your body will clear it on its own.
Some forms of the virus can cause cervical abnormalities that
clear up when the virus is gone. In some women, however, the
virus stays for a number of years and cervical abnormalities may
develop into cancer if left untreated. HPV was found in your
sample.
Borderline or mildly dyskaryotic test result, HPV negative
These [minor abnormalities] are not cancer. A minor
abnormality means that there are small changes to the cells of
your cervix, which are not unusual. Because your result showed
these changes your sample was tested for the Human Papilloma
Virus (HPV), which is a very common infection of the cervix.
HPV was not found. This means that you are at very low risk of
developing cervical cancer of the cervix.
Borderline or mildly dyskaryotic test result, HPV not tested
Centre 1
The report from the laboratory showed that the smear was mildly
abnormal, which means that there are small changes to your
cervix.
Invited for repeat smear test—These changes sometimes happen and
are not cancer, and in most cases do not lead to it. It is important
to give these changes a chance to return to normal by themselves
without treatment. Your next test is due [date] and we will send
you a reminder to make an appointment. If you would like to talk
about the result, please contact your GP or the person who took
the smear.
Referred for colposcopy—Around one woman in twelve has an
abnormal smear and it is unlikely that you have cancer. However,
you may need treatment, and in most cases this results in a
complete cure. If you have not already received a letter inviting
you for an appointment, please contact your GP or the person
who took the smear to discuss the result. If further investigation
is needed, it will involve an examination (colposcopy) at a
hospital outpatient clinic, to determine whether any treatment is
needed. The enclosed leaflet tells you more about abnormal
results.
Centre 2
Invited for repeat smear test—Your recent smear test taken on [date]
shows a minor change. If your test was taken at your GP surgery
or local community clinic, please contact the person who took
your test to discuss the result. A repeat test will be advisable on
[date] and your smear taker will tell you when to make an
appointment.
Referred for colposcopy—The result of your recent smear, taken on
[date] is now available. If your test was taken at your GP surgery
or local community clinic, please contact the person who took
your test to discuss the result.
Normal smear test result
Women who have regular smears are much less likely to develop
cancer of the cervix, but no screening programme can prevent
every single case of cancer, so, if you develop any unusual
bleeding, pain or any other symptoms that concern you, before
your smear test is due, please contact your doctor.
Primary care
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Understanding of smear result was assessed by asking women to
state what they believed their result meant for their current
health (see table 4 for response options). The correct responses
for all women is that they were very unlikely, or unlikely, to have
cervical cancer.
We also recorded age, highest educational achievement, eth-
nic origin, and history of smear results.
Analysis
Differences in the demographic and clinical characteristics of the
groups were assessed using ANOVA and 2 tests. We tested the
study hypotheses using ANCOVA to control for differences in
age, education, centre, and smear history in the groups, with
three planned linear contrasts: normal versus all abnormal bor-
derline or mildly dyskaryotic test results; borderline or mildly
dyskaryotic test results in HPV positive women versus all other
groups; borderline or mildly dyskaryotic results in women who
were not tested for HPV versus borderline or mildly dyskaryotic
and HPV negative. We used linear trend analysis to confirm the
predicted pattern of responses across the four study groups, and
multiple linear regression to ascertain the best predictors of
anxiety in women who received HPV positive results.
Results
The four study groups differed in age, educational level, and
whether or not this was their first smear test (table 1). We
controlled for these three variables when assessing differences in
emotional outcomes between the groups (table 2). In addition,
we controlled for centre, although it was unrelated to any of the
outcome variables in the study.
Analysis of covariance (with age, education, centre, and smear
history as covariates) showed that the groups differed
significantly in anxiety (F3,1218 = 4.44, P = 0.004), distress
(F3,1271 = 5.37, P = 0.001), and concern (F3,1280 = 242.44, P < 0.001).
Planned contrasts confirmed two of the three research
hypotheses. Firstly, the group with normal test results had
significantly less anxiety (t= 2.19, P = 0.028), distress (t= 2.06,
P = 0.040), and concern (t= 24.64, P < 0.001) than the three
groups with abnormal test results, taken together. Secondly, the
HPV positive group had significantly higher anxiety (t= 3.11,
P = 0.002), distress (t= 3.252, P = 0.001), and concern (t= 13.391,
P < 0.001) than the other three groups taken together. The third
hypothesis was not supported: women who had abnormal smear
test results who were HPV negative did not have lower anxiety
(t= 0.064, P = 0.949), distress (t= 0.827, P = 0.409), or concern
(t= 0.852, P = 0.394) than women who had abnormal smear test
results but were not tested for HPV. Although this third hypoth-
esis was not supported, a trend analysis showed a significant lin-
ear trend for all mean scores for all three outcome measures:
anxiety (F1,1218 = 12.73; P = 0.0003), emotional distress
(F1,1271 = 15.46; P = 0.00009), and concern (F1,1280 = 561.94;
P < 0.00001) when the groups were ordered as presented in table
2, in ascending order of risk of developing cervical cancer.
All groups viewed cervical cancer as extremely serious (table
3), but they differed in their perceptions of the risk of developing
it (F3,1324 = 25.51; P < 0.0001): women who were HPV positive
perceived their risks as greater than all other groups (Tukey post
hoc contrast tests). Perceptions of risk also followed a significant
linear trend (F1,1324 = 76.08; P < 0.0001) when the groups were
ordered in ascending order of actual risk.
Forty one per cent of women stated they were unaware of
what HPV was. This was more common in women not tested for
HPV than in those tested. In all groups, women who were famil-
iar with HPV perceived HPV infection as important in causing
cervical cancer, although those with an abnormal result who had
not been tested for HPV perceived it as less important than did
all other groups (F3,778 = 3.42, P = 0.017). Although most of the
women tested for human papillomavirus knew what HPV was,
25% (95% confidence interval 21% to 28%) of HPV positive
women stated that they did not know what it was.
The groups also differed in their understanding of their
results (2 = 194.13, df = 12, P < 0.001; table 4). Compared with
women receiving normal results, those receiving abnormal
results were less likely to think their result meant they definitely
did not have, or were very unlikely to, have cervical cancer.
Women with abnormal results, whether tested for HPV or not,
were less likely to know what their results meant than did women
receiving a normal result (2 = 77.96, df = 3, P < 0.001), with 26%
(22% to 29%) of those who tested HPV positive stating that they
did not know what this meant for their health.
We entered all variables in the linear multiple regression,
apart from perceived importance of human papillomavirus in
causing cervical cancer (as 25% of women failed to respond to
this item). Of these, only three variables independently predicted
anxiety (R2 = 0.103, adjusted R2 = 0.084, P < 0.001): age, with
younger age being associated with higher anxiety (= − 0.11,
Table 1 Demographic and clinical characteristics of women given results of cervical smear and human papillomavirus (HPV) tests. Values are numbers
(percentages) unless stated otherwise
Characteristic Normal result (n=366)
Abnormal results
Anova and 2 tests P valueHPV negative (n=331)
Not tested for HPV
(n=143) HPV positive (n=536)
Mean (SD) age (years) 40.2 (12.2) 40.5 (11.3) 35.4 (10.4) 31.6 (9.7) F = 65.01 <0.001
College education 45 (155) 36 (112) 42 (55) 50 (258) 2 = 17.21 0.001
White ethnic origin 96 (352) 96 (316) 98 (129) 97 (516) 2 = 0.99 0.80
First smear test 8 (31) 6 (19) 8 (12) 17 (90) 2 = 31.09 <0.001
Previous abnormal test results 42 (155) 45 (149) 43 (61) 39 (211) 2 = 2.80 0.42
Table 2 Emotional outcomes after receipt of results of smear test among women tested or not tested for human papillomavirus (HPV). Values are adjusted
means (SE)
Variable Normal result (n=366)
Abnormal result
F (P value)HPV negative (n=331) Not tested for HPV (n=143) HPV positive (n=536)
State anxiety (S-STAI-6) 36.4 (0.7)* 37.6 (0.7)† 37.7 (1.2)† 39.6 (0.6)‡ 4.44 (0.004)
Emotional distress (GHQ-12) 2.0 (0.1)* 2.1 (0.2)† 2.4 (0.3)† 2.8 (0.2)‡ 5.37 (0.001)
Concern about test result 5.2 (0.1)* 8.8 (0.1)† 9.1 (0.2)† 9.7 (0.1)‡ 242.46 (<0.001)
Means with the same symbols do not differ (P>0.05) by planned linear contrasts. Means with different symbols in a given row differed significantly.
Primary care
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P = 0.033); perceived risk of developing cervical cancer (= 0.17,
P < 0.001); and reporting not knowing the meaning of the smear
test result (= 0.17, P = 0.001). Figures 1 and 2 show the associa-
tions between anxiety and the two strongest predictors. Two of
these three variables were also predictive of distress (R2 = 0.073,
adjusted R2 = 0.068, P < 0.001) and concern (R2 = 0.138, adjusted
R2 = 0.133, P < 0.001): perceived risk of developing cervical can-
cer (distress = 0.20, P < 0.001; concern = 0.24, P < 0.001) and
reporting not knowing the meaning of the result (distress
= 0.15, P < 0.001; concern = 0.24, P < 0.001).
Discussion
Informing women with borderline or mildly dyskaryotic smear
test results that they are positive for HPV is associated, at least in
the short term, with raised levels of state anxiety, general distress,
and concern, compared with women receiving normal or
cytologically abnormal smear test results. Anxiety, distress, and
concern were higher when the perceived risk of developing cer-
vical cancer was greater, and in women who reported not under-
standing the meaning of their test results. The mean level of
anxiety in this sample was similar to that seen in general medical
and surgical patients just before surgery.17 In women informed of
a borderline or mildly dyskaryotic smear test result, receiving an
HPV negative result was not reassuring.
Some anxiety is to be expected after receiving abnormal cer-
vical smear test results; for some women, it may provide the nec-
essary motivation to adhere to recommended management.
However, raised anxiety can adversely effect information
processing, impairing the ability to process complex information
and leading to a bias towards processing threatening
information.18 Paradoxically, these effects can serve as barriers to
processing the information that has the greatest chance of
reducing anxiety. We are carrying out a six month follow up to
see if these effects endure, but evidence from systematic reviews
suggests that they will have dissipated.19
Women receiving borderline or mildly dyskaryotic test results
know that their chances of developing cervical cancer are higher
than if they had received normal results. Of concern, however, is
that they seem to perceive these chances to be of a magnitude
beyond that indicated by their results.20 Most women thought
Table 3 Perceptions of the threat of cervical cancer of women given different results of cervical smear and human papillomavirus (HPV) tests. Values are
means (SEs) unless otherwise stated
Perception Normal results (n=366)
Abnormal results
F (P value)HPV negative (n=331) Not HPV tested (n=143) HPV positive (n=536)
Perceived severity (2 seven-point
scales)
12.4 (0.1)* 12.3 (0.1)* 12.1 (0.2)* 12.3 (0.1)* 1.13 (0.334)
Perceived risk (seven-point scale) 3.7 (0.1)* 3.9 (0.1)* 4.1 (0.1)* 4.4 (0.1)† 25.51 (<0.0001)
% (No) unsure what HPV is 54 (199) 38 (125) 62 (89) 25 (133) —
Perceived importance of HPV in
the development of cervical
cancer (by women who knew
what HPV is)
5.9 (0.1)* 5.9 (0.1)* 5.3 (0.3)† 5.8 (0.1)* 3.42 (0.017)
Means with the same symbols do not differ (P>0.05) by Tukey post hoc tests. Means with different symbols in a given row differed significantly.
Table 4 Understanding of the meaning of smear test results of women given different results of cervical smear and human papillomavirus (HPV) tests.
Values are percentages (numbers)
Statement Normal result (n=366)
Abnormal results
HPV negative (n=331) Not tested for HPV (n=143) HPV positive (n=536)
I definitely do not have cervical cancer 31 (112) 12 (39) 15 (21) 12 (63)
I am very unlikely to have cervical cancer 39 (143) 29 (94) 19 (27) 19 (103)
I am unlikely to have cervical cancer 27 (97) 38 (125) 39 (56) 35 (187)
I am likely to have cervical cancer 0 5 (16) 8 (11) 8 (44)
I have cervical cancer 0 0 0 0
I don’t know 3 (12) 16 (53) 19 (27) 26 (137)
Perceived risk of developing cervical cancer in next 10 years
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Fig 1 Associations between state anxiety and perceived risk of developing
cervical cancer (measured on seven point scale) in women with an abnormal
smear result and positive test results for human papillomavirus
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that they were quite likely or very likely to develop cancer in the
next 10 years (fig 1); this suggests a large overestimate of the true
likelihood. Providing women with the absolute likelihood may
diminish their perceived risks and, in turn, diminish anxiety, dis-
tress, and concern.
Perceptions of the prevalence of a health threat also affect
how serious it is perceived to be, with threats perceived as more
common being seen as less serious.21 Women were informed that
human papillomavirus is “a very common infection of the
cervix,” but we do not know how they interpreted this. It is
estimated that about 20% of young women and about 5% of
women aged over 35 are infected at any one time.22 In women
with borderline or mildly dyskaryotic cervical smear test results
the prevalence is higher.22 Informing women of the actual preva-
lence of HPV infection could therefore reduce their anxiety, dis-
tress, and concern.
An appreciable number (22% (217/1003)) of women with
abnormal test results stated that they did not know what their
results meant. In HPV positive women, not knowing what their
results meant was associated with extremely high levels of anxi-
ety. The descriptive, cross sectional nature of the study does not
allow the causal nature of this association to be established. It
seems plausible, however, that not knowing what a result means,
with the attendant uncertainty, could result in high levels of anxi-
ety. Similarly, if women with negative results on HPV testing
knew what this result meant in terms of the likelihood of having
cervical cancer in the near future, they might feel more reassured
and hence less anxious, distressed, and concerned than if they
had not been tested.
Age was the least strong predictor of anxiety in women who
were HPV positive, with anxiety diminishing with age. Previous
research has also shown evidence of this association between
ageing and reduced anxiety.23
Although many of the women receiving borderline or mildly
dyskaryotic results overestimated their chances of having or
developing cervical cancer, a substantial minority of women with
normal results (31%) underestimated their chances, erroneously
believing that they definitely do not have cervical cancer. More
research is needed to evaluate how to avoid such false
reassurance,24 with its attendant adverse effects of delays in seek-
ing help in the face of symptoms, and an increase in the
likelihood of litigation.25
Limitations of study
The generalisability of the results is limited by the sample.
Although the response rate of 63% is good for a mailed survey,26
the sample under-represents women from ethnic minority
groups and women with no educational qualifications. Given the
association between educational level, knowledge, and under-
standing of complex health information,27 our study could
under-represent the distress that HPV testing can cause in gen-
eral population samples of women undergoing cervical
screening.
Conclusion
Studies are needed to determine, firstly, how to avoid some of the
anxiety, distress, and concern caused by positive results on HPV
testing and, secondly, how to provide some reassurance for
women receiving negative results.
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